打击回流药人人有责

Core Insights - The National Medical Insurance Administration has revealed typical cases of drug tracing codes to combat the issue of returned drugs, highlighting the effectiveness of digital technology in regulatory enforcement and the government's firm stance against this illegal practice [1][2] Group 1: Overview of Returned Drugs - Returned drugs refer to pharmaceuticals that have been illegally retrieved from the legitimate medical distribution channels and reintroduced into the market, posing significant risks to public health and disrupting market order [1] - Illegal activities include enticing insured individuals to resell medical insurance drugs and repackaging expired drugs for resale, which undermines the integrity of the pharmaceutical market and threatens the safety of drug use [1] Group 2: Technological Advancements in Regulation - The implementation of drug tracing codes is changing the landscape of drug regulation, allowing for the identification of multiple sales scan records for a single drug package, which may indicate returned or counterfeit drugs [1] - A societal consensus has emerged around the necessity of scanning drugs before purchase and sale, further reducing the space for returned drugs to operate [1] Group 3: Challenges and Solutions in Governance - Addressing the issue of returned drugs requires a multifaceted approach, including increasing the legal consequences for offenders and enhancing collaboration among various regulatory bodies [2] - Establishing a unified data standard and a data-sharing mechanism among departments such as medical insurance, health, and market regulation is essential for improving oversight and governance efficiency [2] - Active participation from pharmacies and consumers in reporting returned drugs is crucial for fostering a safe and compliant pharmaceutical distribution environment [2]